Background
==========

Analysis of the chromosomal background upon which a mutation occurs can be used to reconstruct the origins of specific disease-causing mutations. Mutations that are seen repeatedly on a common haplotype are likely to have descended from a common ancestor, and are referred to as \"founder mutations\". Several founder mutations of the breast and ovarian cancer susceptibility gene *BRCA1*have been identified in individuals of many different ancestries, including families of Ashkenazi Jewish (187delAG, 5385insC) \[[@B1]\], French Canadian (C4446T, 2953del3+C) \[[@B2],[@B3]\], Dutch (2804delAA and Alu-mediated deletions encompassing exons 13 and 22) \[[@B4],[@B5]\], and Polish (5385insC, C61G, 4153delA) \[[@B6]\] origins. The *BRCA1*mutation 1135insA (HGVS nomenclature: c.1135_1136insA) is a frameshift mutation occurring in exon 11. It has previously been identified as one of four founder mutations originating from the Eastern population of Norway \[[@B7],[@B8]\]. In one series, approximately 1% of Norwegian women under the age of 70 years with ovarian cancer carried this mutation \[[@B9]\] and it accounts for \~20% of all *BRCA1/2*mutation carriers demonstrated by DNA testing today in Norway (Møller, unpublished data). This mutation appears on an ancient haplotype, and the age of the 1135insA mutation has not yet been determined. All tested Norwegian individuals with the 1135insA mutation carry the same flanking markers (Møller, unpublished data).

In contrast to other Norwegian founder mutations, the 1135insA mutation has also been reported in other ethnic groups. The mutation has been catalogued 44 times to date in the Breast Cancer Information Core (BIC) database \[[@B10]\] and has been reported to occur in populations throughout Europe including Spain, Norway, the Netherlands, Austria, Italy, as well as in Latin America and North America. These observations raise the question whether *BRCA1*: 1135insA is an ancient mutation that has arisen once, or whether it has occurred several times in human history. The issue is relevant when ethnic-specific mutation panels are used as a pre-screen prior to complete exon-by-exon evaluation of *BRCA1/2*. To address this question, we performed haplotype analysis of the *BRCA1*region in unrelated carrier families of Norwegian, Italian, French Canadian, and Dutch descent.

Methods
=======

Families containing individuals carrying the *BRCA1*:1135insA mutation were recruited into the study via high-risk cancer genetics clinics at McGill University, Montreal, Quebec, Canada, VU University Medical Center and the National Cancer Institute, Amsterdam, The Netherlands, and The Department of Cancer Genetics, Olso, Norway. Appropriate institutional informed consent guidelines were followed for all recruited patients. All mutation identification was performed by direct sequencing in the laboratories of the primary investigators at McGill University, Montreal; the National Cancer Institute, Amsterdam and Haukeland University Hospital, Bergen. Polymorphic microsatellite repeat markers located within (D17S855, D17S1322, D17S1323) and adjacent to (D17S1325) the *BRCA1*locus were used for haplotype analysis. We amplified 100ng of genomic DNA from each subject by PCR for each marker using radioactively labelled nucleotides (primer sequences, marker positions and PCR conditions are given in Table [2](#T2){ref-type="table"}). PCR products were separated on 5% acrylamide/urea denaturing gels at 70W for 1h45 and alleles were visualized by autoradiography.

###### 

Haplotype analysis of unrelated, *BRCA1*1135insA carriers

  **Marker**     Norway   B856   B050   NKI   Mon270   MonDS   Mon1467
  -------------- -------- ------ ------ ----- -------- ------- ---------
  **D17S1325**   218      216    216    216   216      198     198
  **D17S1323**   162      158    158    158   158      150     150
  **D17S1322**   131      125    125    125   125      122     122
  **D17S855**    150      146    146    146   146      150     150

Norway: Six Norwegian families \[8\]

B856, B050, NK1: Dutch families (Amsterdam)

Mon270, MonDS: Italian families (Montreal)

Mon1467: French Canadian (Montreal)

###### 

Primers used to generate the haplotype

  **Marker**   **Chromosome 17 position**   **Forward Primer**      **Reverse Primer**       **T~m~(°C)**   **Other**
  ------------ ---------------------------- ----------------------- ------------------------ -------------- ---------------
  D17S855      38,458,470                   GGATGGCCTTTTAGAAAGTGG   ACACAGACTTGTCCTACTGCC    57             5 % DMSO†
  D17S1322     38,465,161                   CTAGCCTGGGCAACAAACGA    GCAGGAAGCAGGAATGGAAC     60             \--
  D17S1323     38,491,793                   TAGGAGATGGATTATTGGTG    AAGCAACTTTGCAATGAGTG     60             \--
  D17S1325     38,891,165                   AAAGGTGGCAATTCACAGTTG   GTGATAAAACTCAGTGGTACTC   65-55\*        1× Q solution

All reactions were amplified for 35 cycles \[30s\@95°C, 30s\@T~m~, 30s\@72°C\] and contained 200 uM dCTP/dGTP/dTTP, 24 uM dATP, 10 uCi α^35^S-dATP, 1× PCR buffer and 0.5 U of HotStar Taq DNA polymerase (QIAGEN). †Dimethyl Sulfoxide. \*T~m~starting at 65°C and decreasing by 1°C per cycle for 10 cycles, followed by 25 cycles at 55°C; Q solution from QIAGEN.

Results
=======

Clinical description
--------------------

Haplotype analysis was performed on selected cases from three families recruited from the Hereditary Cancer Clinic of McGill University in Montreal (2 Italian, 1 French Canadian), and three Dutch families from the Netherlands Cancer Institute (NKI) in Amsterdam. Haplotype analysis was previously done in Norway on six families \[[@B8]\]. The index patients were referred because of a personal and/or family history of breast or ovarian cancer and were subsequently found to be carriers of the *BRCA1*: 1135insA mutation. Although not discussed above, the family histories of these cases are consistent with this mutation being highly penetrant for both breast and ovarian cancer. The family histories of the Norwegian families have been described previously \[[@B8]\].

Haplotype analysis
------------------

The results of the haplotype analyses are shown in Table [1](#T1){ref-type="table"}. The 1135insA mutation was found to occur on three distinct haplotype backgrounds. The families from Norway had a unique haplotype (218-162-131-150). The three Dutch families shared a common haplotype (216-158-125-146), which was also found in one Italian family from Montreal. The remaining two families from Montreal -- one family of French Canadian descent and the other of Italian descent -- shared a third distinct haplotype (198-150-122-150).

Discussion
==========

The unique haplotype common to all 6 Norwegian families (218-162-131-150) indicates 1135insA is an ancient founder mutation in the Norwegian population. The Netherlands contained a major port during the Middle Ages with outposts to ports elsewhere in Europe. By the seventeenth century, Amsterdam was the biggest trading port of northern commodities and grain to the Mediterranean \[[@B12]\]. One can hypothesize that these trade routes are one means by which a Norwegian founder mutation, on its original haplotype, may have been passed to various Mediterranean countries and hence to North America. Identification of two other, clearly distinct haplotypes in the families examined here suggests, however, that the mutation likely occurred independently in other populations.

In the BIC database \[[@B10]\], the 1135insA mutation is the 12^th^most common frameshift mutation occurring in *BRCA1*. Since our results suggest it does not have a single origin, it may be a relative \"hot spot\" within the *BRCA1*gene. Recombination events or marker mutations could theoretically account for haplotype divergence from a single, original haplotype but are not likely explanations here. Marker D17S855 in intron 20 is only 6.7 kb from D17S1322 in intron 19, and D17S1322 is 26 kb from D17S1323 in intron 12. Markers in such close proximity are unlikely to undergo extensive recombination events. While recombination could conceivably have occurred between D17S1325, located 400 kb upstream from D171323, and the intragenic markers, the haplotypes observed in our families are not consistent with this scenario. In particular, recombination suppression seems to be present in the genomic region that includes *BRCA1*, making recombination in this region an even more unlikely explanation \[[@B13]\]. On the other hand, the DNA sequence surrounding the mutation includes a run of seven consecutive adenines. *BRCA1*:1135insA is an insertion of one A anywhere in the poly-A area in which it occurs -- the position 1135 is but a convention for nomenclature. This poly-A region may thus create a hot-spot within *BRCA1*for replication errors. Alternatively, the same poly-A stretch may have induced repetitive gene conversions or cross-overs.

The *BRCA2*mutation 8765delAG is another example of an \"ancient\" mutation that has been shown to have recurred in different populations. First described as a founder mutation in Sardinia \[[@B14]\], it has been found on different haplotype backgrounds in different populations, including French Canadians and Yemenite Jews \[[@B15]\]. The mutation occurs within a stretch of DNA where 4 consecutive AGs can be found. It is likely that the genomic context in which the *BRCA1*: 1135insA and *BRCA2*: 8765delAG mutations occur favours errors of small insertions and deletions.

Conclusion
==========

We set out to determine whether *BRCA1*: 1135insA is an ancient mutation that has arisen once, or whether it has recurred several times in human history. Our finding that 1135insA exists on several, clearly distinct haplotypes and the fact that it is found in a homopolymer tract suggests it may have appeared independently several times in the human genome. A clinically relevant implication of our findings is that this recurrent mutation should probably be included in targeted *BRCA1*mutation screening panels in any population, irrespective of ethnic origin. When the ethnic origin is clearly defined, founder mutation panels can, and are used in several centres. A \"pre-screen\" based on the most frequent *BRCA1/2*mutations seen in the BIC could also be considered as a first step, prior to complete gene sequence analysis.
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